AAN 2026 | Rimegepant in pediatric migraine: a retrospective chart review study

So this is another retrospective chart review study that we really wanted to just start to begin to understand the use of rimegepant within pediatric patients who have migraine. This medication is FDA approved in adults, but like a lot of the medications and treatment strategies that we employ, a lot of the times we kind of borrow from adults. So this is an off-label treatment for pediatric migraine, but we were utilizing it in a subset of patients in our clinic. So we really wanted to understand how our patients were doing with it, and even more importantly, the potential safety and tolerability of it. So this was a small sample size of patients who were prescribed rimegepant for the acute treatment of migraine. And what we found is that for those patients, it did seem to be an effective treatment, although this very small N, I cannot make that claim. But I think the more important thing is that it was very well tolerated with very few side effects. Interestingly, in this patient population too, we were able to describe its use in some patient populations that oftentimes are excluded from clinical trials. So there’s one patient who had hemiplegic migraine, a prolonged aura, and so starting to just get a little bit of insight into these patient populations that oftentimes are excluded in the clinical trials when those data come out.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.